氯吡格雷联合依折麦布对冠心病的疗效及血清趋化因子配体1等的影响

Effect of clopidogrel combined with ezetimibe on coronary heart disease and serum CX3CL1

目的研究氯吡格雷联合依折麦布对冠心病(CHD)的疗效及血清趋化因子配体1(CX3CL1)等的影响。方法以诊治的120例冠心病患者为研究对象,随机分为研究组和对照组,每组60例,对照组口服氯吡格雷,研究组给予氯吡格雷联合依折麦布,2组均治疗4周,分析2组的疗效、CX3CL1、卵泡抑素样蛋白1(FSTL1)、血脂水平及不良反应之间的差异。结果研究组患者的总有效率(98.33%)显著高于对照组(88.33%);治疗后2组患者的血脂各项指标均显著改善,且研究组患者的血脂水平优于对照组,2组患者的血清CX3CL1和FSTL1水平均显著下降,且研究组患者的血清CX3CL1和FSTL1水平显著低于对照组;2组患者不良反应比较差异无统计学意义(P>0.05)。结论氯吡格雷联合依折麦布治疗CHD,患者血清CX3CL1和FSTL1水平均显著下降,血脂水平显著改善,安全性较好,建议在临床推广使用。

Objective To study the effect of clopidogrel combined with ezetimibe on coronary heart disease(CHD)and serum chemokine X3 C ligand 1(CX3 CL1).Methods 120 patients with coronary heart disease were randomly divided into study group and control group,60 cases in each group.The control group was given clopidogrel orally.The study group was given clopidogrel and ezetimibe.Both groups were treated for 4 weeks.The difference of treatment effect,CX3 CL1,follistatin-like protein 1(FSTL1),blood lipid level and adverse reactions between the 2 groups was analyzed.Results The total effective rate of the study group(98.33%)was significantly higher than that of the control group(88.33%).After treatment,the indexes of blood lipid in the 2 groups were significantly improved,and the level of blood lipid in the observation group was better than that in the control group.Serum levels of CX3 CL1 and FSTL1 of the study group were significantly lower than of the control group,and there was no significant difference in adverse reactions between the 2 groups(P>0.05).Conclusion The serum levels of CX3 CL1 and FSTL1 in patients with coronary heart disease treated with clopidogrel combined with ezetimibe were significantly decreased,the blood lipid level was significantly improved,and the safety was better.It was suggested that the combination should be popularized in clinic.